China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)
(於香港註冊成立的有限公司)

(Stock Code: 3320) (股份代號: 3320)

NOTIFICATION LETTER 通知信函

27 April 2023

Dear Shareholders,

Notice of Sustainability Report for year 2022

The English and Chinese versions of the current sustainability report of China Resources Pharmaceutical Group Limited' (the "Company") are available on the Company's website at http://www.crpharm.com and the HKExnews's website of the Stock Exchange of Hong Kong Limited at www.hkexnews.hk. You may access the current sustainability report by clicking "Social Responsibility" on the home page of our website, then selecting "Sustainability Report 2022" under "Sustainability Report" section or through the HKExnews's website.

If shareholders have difficulty in gaining access to the current sustainability report posted on the Company's website and you wish to receive printed copy of the current sustainability report, please send a letter stating your request with signature by mail to the Company's Share Registrar, Tricor Investor Services Limited. The address of the Company's Share Registrar is 17/F, Far East Finance Centre 16 Harcourt Road Hong Kong.

Yours faithfully,
For and on behalf of
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Note: This letter is addressed to shareholders and non-registered shareholders ("Non-registered shareholder" means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS)). If you have sold or transferred your Shares of the Company, please disregard this notification letter.

敬啟者:

2022年度可持續發展報告之通知

華潤醫藥集團有限公司(「**本公司**」)的本次可持續發展報告中文及英文版本已上載於本公司網站(http://www.crpharm.com)及香港聯合交易所有限公司之披露易網站(www.hkexnews.hk)。 閣下可於本公司網站主頁按「社會責任」一項,再在「可持續發展報告」項下選擇「2022年可持續發展報告」或在披露易網站瀏覽。

倘 閣下於接收本公司網站上的本次可持續發展報告出現困難及欲要求索取本次可持續發展報告之印刷本,請寄回已簽署書面要求至本公司股份過戶登記處卓佳證券登記有限公司。本公司股份過戶登記處地址為香港夏慤道16號遠東金融中心17樓。

此 致

列位股東 台照

代表 **華潤醫藥集團有限公司** 韓躍偉 主席 謹啟

二零二三年四月二十七日

註: 此函件乃向本公司之股份持有人及非記名股份持有人(「非記名股份持有人」指其股份存放於中央結算及交收系統的人士或公司)而發出。如果 閣下已 經出售或轉讓本公司的股票,請毋須理會本通知信函。